UK's Synthace raises $35M in Series C; Oncology and inflammatory disease biotech Deka hauls in $20M Series A
UK-based AI-assisted R&D biotech Synthace just wrapped up a Series C round, bringing in $35 million.
Per a company statement this morning, the investment will fuel commercial and go-to-market (GTM) growth as Synthace continues to expand across the Atlantic into the US. This includes plans to expand its leadership team by bringing in new VPs of marketing and sales to join US-based Guy Levy-Yurista, Synthace’s CEO.
“To maximize impact, we need to expand access and reach to customers across the globe—at scale. This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries,” said Levy-Yurista in a statement.
Investors included Horizon Ventures and Sofinnova Partners.
US biotech Deka raises $20M in Series A
Maryland-based Deka Biosciences closed a $20 million Series A round, with the assistance of Leaps by Bayer and Lumina Ventures alongside other investors.
Deka, a precision medicine biotech prioritizing cancer and anti-inflammatory diseases, has been focusing on engineered proteins and cytokine-based therapies it calls “Diakines.”
The investment will enable Deka to advance research, hire new people and further expand the development of its platform. The biotech is also hoping to use the funding to help push its lead oncology program past the IND stage and into Phase I trials.